The vaccine against human papillomavirus (), the sexually transmitted virus that causes, will be the most profitable in the U.S. with universal vaccination of children under 12 and girls to reach their efforts to vaccinate girls and women aged including 13 to 21, say Harvard researchers.Haug concern that certain types of HPV, other than HPV 16 and 18 will prove to play an important role in the development of cervical cancer is not justified, Haupt said. ‘The idea of the type of substitution is only theoretical.’
‘Length of vaccines is the key parameter to determine whether vaccination against HPV is profitable,’ says Diane Harper, MD, professor and director of gynecologic cancer prevention research Group at Dartmouth Hitchcock Medical Center and Dartmouth College, Hanover , NH
‘We used mathematical models to simulate the natural history of disease,’ Kim said, ‘then superimposed on these strategies, whether screening or a combination of both.’
And ‘inserted in the various strategies, including rehabilitation programs for 18, 21, or 26. The main objective was to see how any strategy to prevent cervical cancer.
‘We really should be targeting and prioritization of girls, 12 years, before sexual activity,’ said Jane J. Kim, Ph.D., Assistant Professor of Health Decision Science, Harvard School of Public Health and lead author of the study
To a point, the recovery program was good, too. ‘We found the vaccine until the age of 18 years has always been good,’ said Kim. ‘Until the age of 21 has been enhanced with generous assumptions about its effectiveness. Up to 26 years was still attractive in terms of cost effectiveness
Kim concludes that, while most girls of 12 years receive the vaccine, their screening for cervical cancer, such as Pap tests and may start a little ‘later than recommended by the CDC, from within three age at first intercourse and no later than 21 years. And the projections that can be made a little ‘less frequently as every three to five years. HPV vaccine: Second Opinion
The new analysis points out that the CDC has recommended vaccination of preadolescent girls, said Rick Haupt, MD, MPH, executive director of clinical research at Merck Research Laboratories, West Point, Pa. Merck’s Gardasil.
It will take time, she and others acknowledge. In the meantime, ‘we need to educate girls and women that the vaccine should be used with the current control system and is not a substitute for life goes on Pap screening,’ said Harper. HPV vaccine: See Industry
In an editorial accompanying the study, Charlotte J. Haug, MD, Ph.D. ‘The bad news is that the overall effect of vaccines on cervical cancer remains unknown,’ he writes.
‘But it’s a very interesting concept and we certainly continue to do research and checked to see if it will work,’ said Haug. ‘We vaccinate girls, and see the effect in 20 years.’
Kim’s team is connected to a hypothesis that the effectiveness of the vaccine could last a lifetime – which is still unknown because the vaccine is too new to try.
While the Harvard model did not consider cost to vaccinate up to 26 years, the model has value in the Merck vaccine show up at the age of 26 years, Haupt, who explains that the models used in analysis are complex and can differ.
In July 2008, the CDC and the FDA have said it received 7,802 reports of adverse effects among those vaccinated with Gardasil, even if the vaccine has not been proved responsible for one of these events.
He stressed that, although two strains of HPV – 16 and 18 – are seen as responsible for the majority of all cervical cancers and are targets for vaccination against HPV, some strains can emerge to cause cancer, too.
‘We know that the risk of an ACL tear is much higher in females, between two to ten times, but this is the first study to show that women are at increased risk of subsequent surgery after ACL reconstruction,’ The Dr. Marx said.
After the FDA approved the HPV vaccine Gardasil in 2006, the CDC has recommended routine vaccination of girls aged 11-12 and catch-up vaccination of girls and women aged 13 to 26. Vaccination strategies against HPV
The study, also published in The New England Journal of Medicine, is one of the many surveys conducted by Kim and colleagues over the years on the prevention of cervical cancer, which has infected more than 11,000 U.S. women in 2007 and 3600 killed .
Kim has collected data to predict both health and economic outcomes of HPV vaccination of girls aged 12, with catch-up vaccination for a period of five girls between 13 and 21 coupled with routine cervical cancer screening.